Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to “Strong Sell” at Wall Street Zen

Seres Therapeutics (NASDAQ:MCRB) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Price Performance

MCRB opened at $1.98 on Friday. The stock has a market capitalization of $20.18 million, a price-to-earnings ratio of -0.40 and a beta of 0.44. Seres Therapeutics has a twelve month low of $1.67 and a twelve month high of $29.98. The company has a 50-day simple moving average of $3.34 and a 200 day simple moving average of $6.85.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.63). The firm had revenue of $0.59 million during the quarter, compared to the consensus estimate of $6.35 million. Seres Therapeutics had a negative net margin of 2,209.55% and a negative return on equity of 194.42%. Sell-side analysts anticipate that Seres Therapeutics will post -6.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A hedge fund recently bought a new stake in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.